Program Goals

The purpose of this CME activity is to educate practicing physicians and other healthcare professionals about the metabolic consequences of psychiatric medications and options for management.  We will review the evidence of the metabolic consequences of different classes of psychiatric medications, with an emphasis on antipsychotics, mood stabilizers and antidepressants. We will look at the data on the contribution of metabolic factors on the significantly reduced lifespan of those with severe mental illnesses. We will discuss the options for management of metabolic side effects including pharmacologic (metformin, newer weight loss drugs such as GLP-1 agonists) and lifestyle (trials involving comprehensive lifestyle interventions including the ketogenic diet).  We will discuss the concept of individualized risk benefit analysis in the context of these populations.

Target Audience

The main target audiences are primary care and psychiatry physicians, nurse practitioners, and physician assistants. We may also consider targeting licensed mental health therapists and dieticians.

Learning Objectives

After completing this activity, the participant should be better able to:

1. Explain the metabolic consequences of different classes of psychiatric medications.
2. Describe recommended metabolic assessments and adherence rates.
3. Discuss individualized risk-benefit analysis for patients with severe mental illness (SMI) on antipsychotic and mood-stabilizing medications.
4. Describe the excess mortality rates of those with serious mental illness and relative contribution of metabolic health on those statistics.
5. Describe the findings of studies on pharmacologic interventions to reduce the burden of the metabolic side effects of psychiatric medications including metformin and GLP-1 agonists.
6. Describe the findings of studies of comprehensive lifestyle interventions on metabolic health in patients with severe mental illnesses.
7. Organize acquired knowledge on the latest findings on metabolic consequences of psychiatric medications and options for management into current practice to better address the needs of their patients, to educate patients, and to optimize patient outcomes.

Faculty

Matthew Bernstein, MD Chief Medical Officer | Ellenhorn LLC Chief Executive Officer & Chief Medical Officer Accord Mental Health LLC Lecturer in Psychiatry, Harvard Medical School

Deanna L. Kelly, PharmD, BCPP Professor of Psychiatry for Mental Illness Research Director, Maryland Psychiatric Research Center University of Maryland School of Medicine

European Accreditation Council for Continuing Medical Education (EACCME)
EACCME Accreditation Statement
The Metabolic Consequences of Psychiatric Medications and Options for Management, made available on https://www.medtalks.com/metabolic-consequences-psychiatric-medications and organized by Dane Garvin Ltd., is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.

Only those e-learning materials that are displayed on the UEMS-ACCME® website have formally been accredited.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits TM . Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

EACCME Term Offering
February 12, 2026 to February 12, 2028

Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.

American Academy of Family Physicians (AAFP) Accreditation
The AAFP has reviewed The Metabolic Consequences of Psychiatric Medications and Options for Management and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 12/15/2025 to 12/15/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.

CME activities approved for AAFP credit are recognized by the AOA as equivalent to AOA Category 2 credit.

American Association of Nurse Practitioners (AANP) Accreditation
AANP Accreditation Statement
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.36 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 25117590. This activity was planned in accordance with AANP Accreditation Standards and Policies. This activity was released on December 15, 2025 and is valid for American Association of Nurse Practitioners credit for two years. Requests for credit must be made no later than December 15, 2027.

Educational Grant
This activity is supported by an educational grant from Metabolic Mind which is a non-profit organization.